When women think about estrogen, they often think about periods, fertility, hot flashes, and menopause. But estradiol—the predominant form of estrogen during the reproductive years—does much more than regulate the reproductive system.
Estrogen receptors are found throughout the body, including in the brain, bones, blood vessels, skin, muscles, vagina, and urinary tract. That helps explain why the hormonal changes of menopause can produce symptoms that seem to involve completely unrelated parts of the body.
And increasingly, researchers are looking at one organ in particular: the brain.
New brain-imaging and Alzheimer’s research is helping us better understand the relationship between estradiol, memory, brain connectivity, and potentially even long-term brain aging. But there is an important distinction women need to understand: evidence that estrogen plays a role in brain function does not automatically mean hormone therapy should be prescribed to improve memory or prevent Alzheimer’s disease.
What Exactly Is Estradiol?
Estradiol, or 17β-estradiol, is the most potent of the naturally occurring estrogens. Before menopause, it is the predominant estrogen in the body and is produced primarily by the ovaries.
Women are born with a finite number of ovarian follicles. As that follicle pool declines with age, ovarian function becomes increasingly unpredictable.
During perimenopause, estradiol doesn’t simply decrease in a straight line. Levels can fluctuate dramatically—sometimes quite high and at other times very low. That hormonal variability is one reason perimenopause can feel like such a roller coaster.
Eventually, there are too few functioning follicles to maintain normal ovarian hormone production. After menopause, ovarian estradiol production falls substantially and remains low. Estrone becomes the predominant circulating estrogen, much of it produced through peripheral conversion of androgens rather than directly by the ovaries.
What Happens When Estradiol Declines?
Hot flashes and night sweats may be the most recognizable symptoms, but estrogen deficiency affects far more than temperature regulation.
Women can experience sleep disruption, mood changes, vaginal dryness, painful intercourse, urinary urgency and frequency, and recurrent urinary tract infections. Over time, estrogen deficiency also contributes to accelerated bone loss and changes in body composition, skin, and the cardiovascular system.
But one of the symptoms women frequently describe in my practice is more difficult to quantify:
“I just don’t feel as sharp as I used to.”
Women may forget why they walked into a room, struggle to retrieve a familiar word, lose their train of thought in a meeting, or feel that multitasking suddenly requires more effort.
We often call this menopause brain fog, and there is a biological basis for it.
Estradiol Is a Brain Hormone, Too
Estradiol plays a role in brain energy metabolism, synaptic function, inflammation, blood flow, and areas involved in learning and memory, including the hippocampus and prefrontal cortex.
Research has found that certain aspects of cognition, particularly verbal learning and memory, can temporarily change during the menopausal transition.
That doesn’t mean menopause causes dementia, nor does it mean every forgotten name or misplaced set of keys is caused by estrogen.
Brain fog is likely multifactorial.
Fluctuating estradiol may contribute directly, but consider what else is happening to many women during this stage of life. Hot flashes can repeatedly interrupt sleep. Anxiety and mood symptoms may emerge or worsen. Women may be balancing careers, children, aging parents, and chronic stress.
All of those factors can affect concentration and memory.
For most healthy women, measurable cognitive changes during the menopausal transition tend to be relatively subtle and may stabilize after the transition.
The bigger question researchers are now asking is whether estrogen loss at midlife could also influence women’s long-term brain health.
What New Brain Imaging Research Is Showing
Recent neuroimaging research is making the estrogen-brain connection particularly interesting.
Studies examining women performing memory tasks have found associations between estradiol levels and functional connectivity within brain networks involved in memory.
There is a plausible biological explanation.
The hippocampus and surrounding memory networks contain estrogen receptors. Estradiol influences synaptic plasticity—the brain’s ability to form and reorganize connections—and also affects glucose utilization, blood flow, neurotransmitter signaling, and communication between brain regions involved in encoding and retrieving memories.
If functional connectivity differs according to estradiol levels during a memory task, one possible interpretation is that estradiol influences how efficiently memory networks communicate or recruit different brain regions during recall.
Other imaging research has similarly associated estradiol with hippocampal connectivity and activation of frontal and temporal brain regions during memory tasks.
But this is where we need to be careful.
An association between estradiol and brain connectivity does not prove that giving a woman estradiol will improve her memory.
Brain imaging can help us understand the biology of menopause, but an interesting MRI finding is not the same thing as a clinical treatment recommendation.
Could Estrogen Protect Against Alzheimer’s Disease?
This may be one of the most important—and most complicated—questions in menopause research.
Women represent a disproportionate share of people living with Alzheimer’s disease, and researchers have increasingly questioned whether the dramatic hormonal changes occurring at menopause could play some role in that vulnerability.
Recent research has added intriguing clues.
A 2026 study examining menopausal hormone therapy and Alzheimer’s pathology found that women who had used estrogen-only menopausal hormone therapy had less Alzheimer’s-related brain pathology and were less likely to develop dementia.
Because researchers examined Alzheimer’s pathology at autopsy, the study provides a different type of information than studies based solely on cognitive testing or clinical dementia diagnoses.
But it was observational research.
That means we can say there was an association. We cannot say the study proved estrogen prevented Alzheimer’s disease.
Other recent research has examined Alzheimer’s biomarkers and found that early or continuous transdermal 17β-estradiol was associated in some studies with more favorable biomarker patterns, including lower phosphorylated tau and preservation of glucose metabolism in brain regions vulnerable to Alzheimer’s disease.
The findings, however, have not been consistent across all hormone formulations or studies.
This emerging evidence is changing the conversation, but it isn’t yet changing the fundamental clinical recommendation.
We cannot currently tell women that estrogen therapy prevents Alzheimer’s disease, and systemic hormone therapy should not be prescribed solely for dementia prevention.
So, Should Women Take Estradiol for Brain Fog?
Not solely for brain fog.
Randomized clinical trials have not established menopausal hormone therapy as a cognitive-enhancing medication or dementia-prevention treatment.
But there is an important nuance.
Imagine a woman in her early 50s experiencing significant hot flashes, night sweats, disrupted sleep, and brain fog. If she is otherwise an appropriate candidate for menopausal hormone therapy, I may consider hormone therapy for her established menopausal symptoms.
As her hot flashes and sleep improve, she may also report that her concentration and mental clarity improve.
That is very different from prescribing estrogen specifically as a memory-enhancing drug.
Brain fog can absolutely be part of menopause, and estrogen plays an important role in the brain. But treating menopausal symptoms with estrogen and prescribing estrogen specifically to prevent Alzheimer’s disease are not yet the same thing.
What Does Estradiol-Based Hormone Therapy Look Like?
Menopausal hormone therapy essentially replaces some of the hormones that decline as ovarian function decreases.
When estradiol is used, one option is bioidentical 17β-estradiol, meaning it has the same molecular structure as estradiol produced by the human body. It can be administered orally or through the skin using a patch, gel, or spray.
Hormone therapy doesn’t make the ovaries begin producing estrogen again. We are supplying estradiol from outside the body to replace some of what has been lost.
For women who still have a uterus, systemic estrogen generally needs to be combined with adequate progesterone or another progestogen to protect the endometrium.
Low-dose vaginal estrogen is different. It is primarily a local treatment for genitourinary syndrome of menopause and typically results in minimal systemic absorption.
When appropriate for the individual patient, I frequently favor transdermal 17β-estradiol combined with micronized progesterone in women who have a uterus.
Transdermal estradiol bypasses first-pass metabolism through the liver, and observational evidence suggests it has a more favorable blood-clot risk profile than oral estrogen.
But there is no single hormone regimen that is right for every woman.
Hormone Therapy Should Be Individualized
For healthy women with bothersome menopausal symptoms who are younger than 60 or within approximately 10 years of menopause onset, the benefit-risk profile of menopausal hormone therapy is generally favorable when there are no contraindications.
Hormone therapy may not be appropriate—or may require substantially more individualized assessment—for women with certain estrogen-sensitive cancers, unexplained vaginal bleeding, a history of blood clots or stroke, significant cardiovascular disease, thrombophilia, or active liver disease.
Route, dose, formulation, age, medical history, timing relative to menopause, whether a woman has a uterus, and personal preferences all matter.
The goal should not be to chase a particular estradiol number on a laboratory report. The goal is to select an appropriate formulation and dose for a clearly defined clinical indication while balancing benefits and risks.
Four Questions to Ask Before Starting Estradiol
Before starting hormone therapy, I encourage women to think through four questions.
What am I trying to treat? Identify the symptoms affecting your quality of life, whether those are hot flashes, night sweats, sleep disruption, vaginal or urinary symptoms, or another menopause-related concern. Hormone therapy should have a treatment goal.
Where am I in the menopause transition? Age and time since menopause matter when assessing the benefit-risk profile of systemic hormone therapy.
What does my medical history mean for my individual risk? A clinician should review factors such as estrogen-sensitive cancers, unexplained bleeding, blood clots, stroke, cardiovascular disease, liver disease, and other relevant medical history.
Which formulation and route make the most sense for me? “Hormone therapy” isn’t one medication. Oral, transdermal, and vaginal therapies have different purposes and considerations, and women with a uterus need appropriate endometrial protection when using systemic estrogen.
The Bigger Picture: Estradiol Is More Than a Reproductive Hormone
Perhaps the most important shift occurring in menopause medicine is recognizing how extensively estrogen functions outside of reproduction.
Estradiol is also a brain hormone.
Emerging imaging research is helping explain why women can experience very real cognitive changes as estrogen fluctuates during the menopausal transition. Newer research into Alzheimer’s pathology and biomarkers is also raising important questions about whether the timing, route, and formulation of hormone therapy could ultimately matter for long-term brain aging.
Those are exciting questions, but they aren’t settled questions.
Understanding that estradiol affects the brain and proving that estrogen should be prescribed specifically to enhance cognition or prevent Alzheimer’s disease are two very different things.
For now, the best approach is to treat the woman—not a laboratory number, an MRI image, or the fear of a future disease.
Hormone therapy should be considered in the context of her symptoms, age, medical history, risk factors, goals, and where she is in the menopausal transition.
And women experiencing brain fog deserve to know one thing clearly: the cognitive changes they notice during menopause can be real. We are simply still learning exactly what estrogen’s role in those changes means for treatment—and for women’s brains over the decades that follow.
References
Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850-1857. doi:10.1212/WNL.0b013e3181a71193.
Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am. 2011;38(3):519-535. doi:10.1016/j.ogc.2011.05.007.
Jacobs EG, Weiss BK, Makris N, et al. Impact of sex and menopausal status on episodic memory circuitry in early midlife. J Neurosci. 2016;36(39):10163-10173. doi:10.1523/JNEUROSCI.0951-16.2016.
Brown ES, et al. Estradiol associations with brain functional connectivity in postmenopausal women. Psychoneuroendocrinology. 2024.
Brown ES, et al. Estradiol modulated brain connectivity in females during midlife performing an episodic memory task. Brain Imaging Behav. Published online June 5, 2026. doi:10.1007/s11682-026-01167-1.
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.
Bruno D, et al. Association between menopausal hormone therapy and Alzheimer disease neuropathology. Neurology. 2026;107(5):e218413. doi:10.1212/WNL.0000000000218413.
Shadyab AH, et al. Randomization to hormone therapy and changes in plasma biomarkers of Alzheimer’s pathology: the Women’s Health Initiative Memory Study. Maturitas. 2026;207:108873.
US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(17):1740-1746. doi:10.1001/jama.2022.18625.